Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study has been completed.
Study NCT00766363 Information provided by EnVivo Pharmaceuticals, Inc.
First Received on October 1, 2008. Last Updated on April 18, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer's Disease
Central Nervous System Diseases
Additional conditions recognized in this trial
Alzheimer Disease
Nervous System Diseases
More general conditions related to this trial
Brain Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Neurodegenerative Diseases
Tauopathies
Interventions listed in this trial
EVP-6124 (0.1 mg/day)
EVP-6124 (0.3 mg/day)
EVP-6124 (1.0 mg/day)
Comparator: Placebo
Donepezil
Rivastigmine
Additional drug interventions recognized in this trial
Nicotinic Agonists
More general drug interventions related to this trial
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
EnVivo Pharmaceuticals, Inc.
INC Research
Back to top of Main Content
